Drug target prediction using adverse event report systems: a pharmacogenomic approach

Motivation: Unexpected drug activities derived from off-targets are usually undesired and harmful; however, they can occasionally be beneficial for different therapeutic indications. There are many uncharacterized drugs whose target proteins (including the primary target and off-targets) remain unknown. The identification of all potential drug targets has become an important issue in drug repositioning to reuse known drugs for new therapeutic indications. Results: We defined pharmacological similarity for all possible drugs using the US Food and Drug Administration's (FDA's) adverse event reporting system (AERS) and developed a new method to predict unknown drug–target interactions on a large scale from the integration of pharmacological similarity of drugs and genomic sequence similarity of target proteins in the framework of a pharmacogenomic approach. The proposed method was applicable to a large number of drugs and it was useful especially for predicting unknown drug–target interactions that could not be expected from drug chemical structures. We made a comprehensive prediction for potential off-targets of 1874 drugs with known targets and potential target profiles of 2519 drugs without known targets, which suggests many potential drug–target interactions that were not predicted by previous chemogenomic or pharmacogenomic approaches. Availability: Softwares are available upon request. Contact: yamanishi@bioreg.kyushu-u.ac.jp Supplementary Information: Datasets and all results are available at http://cbio.ensmp.fr/~yyamanishi/aers/.

[1]  Jean-Loup Faulon,et al.  Genome scale enzyme–metabolite and drug–target interaction predictions using the signature molecular descriptor , 2008 .

[2]  YamanishiYoshihiro,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008 .

[3]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[4]  Elena Marchiori,et al.  Gaussian interaction profile kernels for predicting drug-target interaction , 2011, Bioinform..

[5]  C. Dobson.  Chemical space and biology , 2004, Nature.

[6]  B. Stockwell.  Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[7]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[8]  Julian Blagg,et al.  Structure–Activity Relationships for In vitro and In vivo Toxicity , 2006 .

[9]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[10]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[11]  Tatsuya Akutsu,et al.  Graph Kernels for Molecular Structure-Activity Relationship Analysis with Support Vector Machines , 2005, J. Chem. Inf. Model..

[12]  R. Altman,et al.  Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.

[13]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[14]  Yasushi Okuno,et al.  Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations , 2011, International journal of medical sciences.

[15]  Russ B. Altman,et al.  A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports , 2012, J. Am. Medical Informatics Assoc..

[16]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[17]  Jean-Philippe Vert,et al.  Protein-ligand interaction prediction: an improved chemogenomics approach , 2008, Bioinform..

[18]  Roded Sharan,et al.  An Algorithmic Framework for Predicting Side-Effects of Drugs , 2010, RECOMB.

[19]  Tatsuya Akutsu,et al.  Protein homology detection using string alignment kernels , 2004, Bioinform..

[20]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[21]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[22]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.